Merck and Co's cancer drug Keytruda to smash sales records b...

Merck & Co's Keytruda cancer immunotherapy is set to become the world's top-selling drug by annual revenue in 2023, smashing sales records set by AbbVie's inflammatory disease drug Humi

NICE says 'no' to regular NHS funding for Roche's Tecentriq ...

NICE has said Roche's Tecentriq (atezolizumab) should not get regular NHS funding in first draft guidance as a treatment for metastastic triple negative breast cancer (TNBC), saying that it

Merck & Co hopes for foothold in early TNBC after Keytruda t...

Merck & Co has unveiled data from its immunotherapy Keytruda that could allow it to gain a foothold in the tough-to-treat triple negative breast cancer (TNBC) indication, and potentiall

ESMO 2019 – new data could unlock bigger market for PARP inh...

AstraZeneca and GlaxoSmithKline could both benefit from new data that should widen the market for PARP inhibitors as first-l

ESMO 2019 - Amgen’s KRAS drug finds colorectal cancer a chal...

Amgen’s KRAS inhibitor AMG 510 has shown little effect in colorectal cancer patients, according to new data reported at the

As ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian...